BAPHON is pleased to promote an informative talk and dinner hosted by Servier Pharmaceuticals.  

Mitchell Cario, MD will be leading a program on ASPARLAS (calaspargas peg-mknl) for the treatment of ALL.  

ASPARLAS is asparaginase with a dierence. Because ASPARLAS is more stable than other pegylated asparaginase, it has a longer half-life. ASPARLAS oers the option of dosing every three weeks as part of a multiagent chemotherapy regimen and has a 36-month shelf life facilitating better product management.1,2 We hope you can attend this important program to help your patients with ALL.

Please contact your Servier representative, Christopher Greig, at christopher.greig@servier.com or 650.380.8934 if you would like to attend this program.

Mitch Cairo March 10th Invite.pdf